Prevention and treatment of bacterial diseases caused by bacterial bioterrorism threat agents

被引:43
作者
Greenfield, RA [1 ]
Bronze, MS
机构
[1] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Infect Dis Sect, Oklahoma City, OK 73190 USA
[2] Oklahoma City Vet Adm Med Ctr, Oklahoma City, OK 73190 USA
关键词
D O I
10.1016/S1359-6446(03)02847-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There is general consensus that the bacterial agents or products most likely to be used as weapons of mass destruction are Bacillus anthracis, Yersinia pestis, Francisella, tularensis and the neurotoxin of Clostridium botulinum. Modern supportive and antimicrobial therapy for inhalational anthrax is associated with a 45% mortality rate, reinforcing the need for better adjunctive therapy and prevention strategies. Pneumonic plague is highly contagious, difficult to recognize and is frequently fatal. Therefore, the development of vaccines against this agent is crucial. Although tularemia is associated with low mortality, the highly infectious nature of aerosolized F. tularensis poses a substantive threat that is best met by vaccine development. Safer antitoxins and a vaccine are required to meet the threat of the use of botulinum toxin as a weapon of mass destruction. In this article, the current status of research in these areas is reviewed.
引用
收藏
页码:881 / 888
页数:8
相关论文
共 56 条
  • [1] ALIBEK K., 1999, Biohazard: the chilling true story of the largest covert biological weapons program in the world, told from the inside by the man who ran it
  • [2] Postexposure prophylaxis against anthrax: Evaluation of various treatment regimens in intranasally infected guinea pigs
    Altboum, Z
    Gozes, Y
    Barnea, A
    Pass, A
    White, M
    Kobiler, D
    [J]. INFECTION AND IMMUNITY, 2002, 70 (11) : 6231 - 6241
  • [3] ARNON SS, 2002, BIOTERRORISM GUIDELI, P141
  • [4] Management of anthrax
    Bartlett, JG
    Inglesby, TV
    Borio, L
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 35 (07) : 851 - 858
  • [5] Bell David M, 2002, Emerg Infect Dis, V8, P222
  • [6] FIELD-EVALUATION OF A HUMAN ANTHRAX VACCINE
    BRACHMAN, PS
    FEKETY, FR
    GOLD, H
    WERRIN, M
    INGRAHAM, NR
    PLOTKIN, SA
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH AND THE NATIONS HEALTH, 1962, 52 (04): : 632 - +
  • [7] Prevention of inhalational anthrax in the US outbreak
    Brookmeyer, R
    Blades, N
    [J]. SCIENCE, 2002, 295 (5561) : 1861 - 1861
  • [8] Bacillus anthracis and antibacterial agents
    Bryskier, A
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (08) : 467 - 478
  • [9] Development of vaccines for prevention of botulism
    Byrne, MP
    Smith, LA
    [J]. BIOCHIMIE, 2000, 82 (9-10) : 955 - 966
  • [10] Antibiotic treatment of experimental pneumonic plague in mice
    Byrne, WR
    Welkos, SL
    Pitt, ML
    Davis, KJ
    Brueckner, RP
    Ezzell, JW
    Nelson, GO
    Vaccaro, JR
    Battersby, LC
    Friedlander, AM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) : 675 - 681